INTRODUCTION
Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder that primarily affects neurons in the striatum and cortex (Albin, 1995; Cudkowicz and Kowall, 1990; Hedreen et al., 1991) . HD is caused by a polyglutamine (polyQ)-encoding CAG expansion in the gene for the huntingtin protein (Htt) (The Huntington's Disease Collaborative Research Group, 1993) . Expression of mutant Htt leads to selective neuronal dysfunction and degeneration despite its ubiquitous expression pattern (Bhide et al., 1996; Gourfinkel-An et al., 1997) . Truncated mutant Htt, in contrast to full-length mutant Htt, induces apoptosis (Martindale et al., 1998) , and mutant N-terminal Htt fragments have been observed in human HD tissue and presymptomatic HD mouse models, suggesting that proteolysis is required for disease progression (Mende-Mueller et al., 2001; Wang et al., 2008; Wellington et al., 2002) . Inhibition of mutant Htt cleavage reduces and in some cases prevents toxicity in vitro and in vivo, indicating a causative role for Htt proteolysis in HD pathogenesis Graham et al., 2006; Kim et al., 1999; Wellington et al., 2000) .
A number of proteases have been shown to cleave mutant Htt. Caspases and calpains are the most widely studied and cleave Htt within the N-terminal region between amino acids 469 and 586 Wellington et al., 2000) . Recent work has identified Htt cleavage sites closer to the N terminus, between amino acids 105 and 167 (Lunkes et al., 2002; Ratovitski et al., 2007; Tanaka et al., 2006) , producing smaller and potentially more toxic mutant polyQ-containing fragments. While these studies have suggested that cathepsins and/or calpains are the proteases responsible for producing these smaller fragments, the exact cleavage sites and identity of the proteases involved have not been unequivocally identified (Kim et al., 2006; Lunkes et al., 2002; Ratovitski et al., 2007) .
Historically, Htt was the first neurodegenerative disease protein identified as a caspase substrate, and our understanding of proteolytic processing of Htt has thus far focused on the cysteine protease families of caspases and calpains Goldberg et al., 1996; Graham et al., 2006; Hermel et al., 2004; Wellington et al., 1998 Wellington et al., , 2002 Yanai et al., 2006) . In this study, we used an unbiased approach to identify other protease families involved in Htt proteolysis and toxicity. From a drug development perspective, this is a particularly attractive approach given that there are 514 known and predicted protease genes present in the human genome, and many of these have existing inhibitory compounds developed as therapeutics for a number of human diseases. One such class of proteases, the matrix metalloproteinases (MMPs) is involved in a number of diverse pathological processes. MMPs are zinc-containing proteolytic enzymes secreted to degrade extracellular matrix proteins (Hornebeck and Lafuma, 1991 ). An imbalance in MMP/TIMP (tissue inhibitor metalloproteinase) activity is implicated in conditions such as rheumatoid arthritis, kidney disease, cardiovascular disease, and cancer (Baker et al., 2002; Konttinen et al., 1999; Ronco et al., 2007) . Recent evidence has linked inhibition of MMPs to reduced neuronal damage after transient cerebral ischemia (Lee et al., 2009 ). MMP-3 and MMP-9 knockout mice have significantly decreased striatal neuronal cell death after intracerebral hemorrhage (Xue et al., 2009 ). Further, intraperitoneal injection of the MMP-3/MMP-9 inhibitor, SB-3CT, showed a decrease in MMP activity and infarct size in the ischemic cortex in a mouse model of stroke (Gu et al., 2005) . While the importance of MMPs in disease has led to the development of a few highly specific MMP inhibitors, further studies are needed to characterize the contribution of MMP family members to normal cell function and disease.
Given that smaller Htt fragments generally yield greater cellular toxicity Martindale et al., 1998) , we designed a high-throughput western blot-based screen to examine the generation of the smallest N-terminal polyQ-containing fragment from full-length Htt. We screened a set of 514 small interfering RNA (siRNA) pools targeting the repertoire of all known and predicted protease genes encoded in the human genome to identify those proteases that when inhibited reduced Htt proteolysis. Our primary screen identified 41 proteases that alter Htt fragment accumulation, and 11 of these were confirmed in retesting. Nine of the eleven proteases are expressed in striatal cells, and their knockdown significantly reduced Htt-mediated striatal cell death in a secondary cellular toxicity screen. Furthermore, decreasing the levels of five of these proteases suppressed mutant Htt induced toxicity in a Drosophila HD model.
Of the nine proteases validated by the secondary screen, three are matrix metalloproteinase family members, suggesting that these enzymes play a role in Htt proteolysis and toxicity. We demonstrate that MMP-10 directly cleaves Htt and reduces (A) siRNA/DNA cotransfection of cells was done in 96-well format, and transfected cells were incubated 48 hr before the addition of epoxomicin to stabilize Htt fragments. Cells were lysed and crude lysates transferred to SDS-PAGE loading buffer for subsequent western blot analysis. The first two columns of each plate contained control transfections-antibody specificity control, nontargeting (NT) siRNA/empty vector (gray wells); negative control:, NT siRNA/Htt 138Q full-length (FL) (lavender wells)-and the rest of the plate contained an individual protease siRNA w/Htt138Q FL DNA (green wells). (B) Each of the rows of the 96-well plate transfections in (A) were loaded onto a single SDS-PAGE gel and subjected to western blotting. The antibody 1C2 (MAB1574) detects two robust nonspecific bands (*) in vector only lanes, while the remaining bands in Htt138Q FL lanes are either unique or dramatically enriched. The bands range from the fulllength protein (FL) to the 55 kDa fragment of interest (arrowhead). (C) Densitometry spectra of the MMP-10 and NT lanes from the western blot shown in (B). Each gel was subjected to densitometric analysis of bands, and the volume ratio of the 55 kDa to FL was compared to the ratio in the NT control lane to identify candidate proteases. See also Figure S1 .
cell death when knocked down in striatal Hdh 111Q/111Q cells. We also find that MMP activity is significantly elevated in mouse models of HD and reduced MMP activity suppresses Htt-induced neuronal dysfunction in Drosophila. These data show that MMPs affect expanded polyQ-Htt proteolysis and toxicity, suggesting this family of enzymes may be relevant therapeutic targets in the disease.
RESULTS

Identification of Proteases Involved in the Generation of the Small N-terminal Mutant Htt Fragment
Given that smaller Htt fragments generally yield greater cellular toxicity Martindale et al., 1998) , we designed a high-throughput western blot-based screen to examine the generation of a small N-terminal polyQ-containing fragment from full-length Htt in a 96-well format ( Figure 1A ). As shown in Figure 1B , this screen allows the analysis of multiple proteolytic cleavage products generated from full-length mutant Htt. Mutant Htt and cleavage products were detected with a monoclonal antibody that recognizes the expanded polyQ stretch in the N-terminus of Htt (1C2). We focused our analysis on the generation of the smallest N-terminal polyQ containing Htt fragment observed, which migrates at 55 kDa ( Figure 1B , indicated by arrowhead). siRNAs directed against all 514 known or predicted human proteases were screened in duplicate for effects on proteolysis of expanded full-length Htt in HEK293T cells using the western blot assay. In this primary screen, 41 initial hits were identified that reduced the levels of the smallest N-terminal Htt fragment (possible aspartyl Htt cleavage product [Lunkes et al., 2002] ) with at least a 30% reduction in expression of the Htt fragment relative to the full-length protein. This analysis was done using densitometry as shown in Figure 1C . The conditions of this assay result in significant knockdown of specific protease targets as demonstrated by western blot analysis of caspases (see Figure S1 available online).
Retesting of these 41 primary hits resulted in 11 of the hits being confirmed by their consistent decrease in the production of the 55 kDa putative aspartyl Htt cleavage product (Table 1) . The proteases identified include members of the calpain family (CAPN5 and CAPN7); the signal peptide protease-like IMP5; an aminoterminal signal peptide protease (SPC18); members of the secreted serine-protease kallikrein family (KLK10 and KLK11); the transmembrane-E3-ubiquitin ligase, RNF128; the MMP-2 interacting integrin, ITGA2B (Choi et al., 2008b) ; and three members of the matrix metalloproteinase family (MMP-10, MMP-14, MMP-23B).
Secondary Screen for Modifiers of Htt Toxicity in Immortalized Mouse Striatal Cells
There is a body of literature suggesting that truncation of the full-length protein is cytotoxic in all polyQ diseases. For Htt protein, the smaller N-terminal truncation products are associated with increased toxicity. Since the 55 kDa product is the smallest detectable Htt cleavage product in our western blot analysis, we predict that blocking production of this fragment will prevent Htt-mediated cell death. To analyze the effect of the 11 initial hits identified in our western blot screen, we developed a Htt-mediated cell death assay relevant to HD. Since HD primarily affects striatal and cortical neurons we used immortalized mouse striatal cell Hdh 7Q/7Q and Hdh 111Q/111Q lines for our secondary screen of cellular toxicity, as well as subsequent genetic and biochemical studies (Trettel et al., 2000) . Previous work in our laboratory has demonstrated that striatal cells from mutant Htt knockin mice have altered calcium handling (Oliveira et al., 2006) and other groups have reported that they are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway (Mao et al., 2006; Milakovic and Johnson, 2005 . Further, siRNA against caspase-3, which serves as a positive control in our assay, reduced caspase activity by 8.7 fold in Hdh 111Q/111Q cells ( Figure 2A ). Having established a robust striatal cellular toxicity assay, we evaluated whether the 11 proteases identified in our primary screen are active in this assay. Intriguingly, siRNA-mediated knockdown of 9 of the 11 proteases results in significant reduction of toxicity in this cell model ( Figure 2B ). KLK10 and KLK11, the two original hits that were negative in this secondary Figure S2 ) that are structurally related zinc-and calcium-dependent enzymes. Some are activated intracellularly by furin proteases and many have been implicated in cancer, stroke, and arthritis.
To further analyze the effect of MMP knockdown in striatal cells, we evaluated whether these proteases were expressed in Hdh 111Q/111Q cells and if the knockdown occurred in response to the siRNA. Western blotting for MMP-10 and MMP-14 demonstrated that they are present in Hdh 111Q/111Q cells at detectable levels, and introduction of siRNAs specific to their messenger RNAs does cause a significant reduction in MMP mRNA and protein expression (Figures 3A and 3B) . We found the level of knockdown correlated with the reduction in caspase activity as titration of siRNA to MMP-10 (or deconvoluted siRNA pools) further reduced protein levels correlating with a reduced caspase-3 activity (data not shown). As shown in Figure 3C , siRNA directed against MMP-10 or MMP-14 significantly reduced caspase activation in Hdh 111Q/111Q cells. We also found that MMP-23B was knocked down by the siRNA treatment and reduced caspase activation in Hdh 111Q/111Q cells (data not shown). The MMP-23B mRNA level of expression in mouse striatal cells and tissue is quite low when compared to MMP-14 (0.00663 ± 0.001 versus 0.5304 ± 0.006; 0.00026 ± 0.00006 versus 0.0078 ± 0.0003). Next, we tested a pharmacologic inhibitor, NNGH, which is a nonpeptidic, potent inhibitor of MMPs. The crystal structure of the catalytic domain of human matrix metalloproteinase 10 has been solved with this molecule (Bertini et al., 2004) . In addition to pharmacologic inhibitors, we tested known endogenous inhibitors of MMPs-TIMP1 and TIMP3 in Hdh 111Q/111Q cells. As shown in Figures 3D and 3E, we found that these inhibitors blocked Htt-mediated toxicity in Hdh 111Q/111Q cells. The specificity of the MMP antibodies was confirmed by overexpressing MMP-10 and MMP-14 in striatal cells ( Figure 4B ). MMP-23B levels did not change in striatal Hdh 111Q/111Q cells when compared to Hdh 7Q/7Q (data not shown).
MMP-10 Is Processed in Striatal Hdh
The proteolytic processing of MMP-10 does not necessarily indicate that levels of active MMP have increased in the mutant Htt cells. We therefore evaluated the MMP activity in striatal Hdh 7Q/7Q and Hdh 111Q/111Q cells. Figure 4C shows that MMP enzymatic activity is significantly increased in striatal Hdh 111Q/111Q cells when compared to Hdh 7Q/7Q using a fluorogenic substrate assay.
MMPs Are Activated in the R6/2 and YAC128 Mouse Model of HD We next examined whether our cell culture results could be recapitulated in mouse models of the disease. We used a full-length Htt (YAC128) and a fragment mouse model (R6/2) of HD. The fulllength HD model provides information about the natural history of proteolysis of full-length Htt and the proteases activated. The fragment model can provide information about the amplification and feedback of proteases once a relevant fragment is formed. The MMP enzymatic activity was assayed in the subregions of the brain in the YAC128 and R6/2 mouse model of HD. Figure 5A shows that MMP enzymatic activity is indeed increased in 16-month-old YAC128 or 10-week-old R6/2 striatum, with a 1.6-to 1.8-fold increase in MMP activity relative to the control striatum. We also examined the MMP enzymatic activity in another polyQ disease, SCA7 (Mookerjee et al., 2009) . As shown in Figure 5A (right panel), MMP enzymatic activity does not increase in SCA7 mice expressing ataxin-7-92Q. This suggests MMP activation is relevant in HD but may not be a feature of other polyQ diseases. We used zymography to analyze the specific activity of the various MMPs in HD mouse brain, after MMP affinity precipitation (using gelatin beads). As shown in Figure 5B , we found elevated MMP activity detected in several bands ranging from 50 kDa to 90 kDa in lysates of the cortex and striatum of R6/2 mouse when compared to controls. The most robust increase in R6/2 lysate activity corresponds to the 50 kDa bands ( Figure 5B ). Since MMP-10 migrates at around 50 kDa in its active form, this result is in agreement with our striatal cell line studies. We cannot exclude the possibility that other co-migrating MMPs may contribute to the observed activity. The band at 90 kDa may represent MMP-9 (MW 92 kDa, arrowhead), a protease activated by MMP-10.
In Situ Gelatinase Activity Since the MMP activity assay and zymography indicated increased levels of MMP activity in R6/2 and YAC128 lysates, we employed an in situ gelatinase assay to evaluate the levels of MMP directly in R6/2 and control tissue sections. In sections from R6/2 mice, we observed increased fluorescence when compared to control in both the striatum and cortex ( Figure 5C ).
Inhibition with the MMP inhibitor 1,10-phenanthroline abolished the fluorescence signal, confirming that the activity was attributable to MMPs ( Figure S3 ). Since MMP family members can be expressed in both glial and neuronal populations, we determined 
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Matrix Metalloproteinases Modify Huntingtin the subpopulation that contained MMP activity by costaining with GFAP (glial specific) or NeuN (neuronal specific). The majority of MMP staining is present in neurons, although some MMP activity does colabel GFAP-positive cells ( Figure S3 ). (Vergote et al., 2006) . To determine whether Htt is a direct substrate for MMP-10 or MMP-14, we incubated cell lysates expressing Htt with the recombinant MMPs. As a control, we included MMP-2, an MMP family member not found to alter HD cellular toxicity or proteolysis in our original screen. As shown in Figure 6A , full-length wild-type or mutant Htt expressed in cellular lysates is a substrate for MMP-10, but not MMP-14 or MMP-2. A cleavage product appears at 48 kDa originating from normal Htt, and 70 kDa for mutant Htt148Q. In vitro translation of Htt15Q (1-1212) also confirmed that Htt is a substrate for MMP-10 but not MMP-14 or MMP-2 ( Figure 6B ). All three MMP family members were equally active against the fluorescent substrate, Mca-Pro-Leu-Dpa-Ala-Arg-NH 2 , suggesting that Htt is a preferred substrate for MMP-10 (data not shown). These data indicate that MMP-10 knockdown suppresses Htt toxicity through its direct effect on Htt cleavage while the effect of MMP-14 knockdown is indirect.
Direct versus Indirect Effects of MMPs on HD-Mediated
MMP-10 Cleaves Htt at Amino Acid 402
MMP-10 appears to cleave Htt in a region closer to the N terminus than the caspase and calpain cleavage products (55-72 kDa) Hermel et al., 2004; Wellington et al., 1998 ) producing a smaller 48 kDa product. Recent in vitro studies suggest Htt is also cleaved at amino acid 167 (Ratovitski et al., 2009 ). Deletion of the residues at this site has no effect on the proteolysis of Htt by MMP-10 ( Figure 6B) . Therefore, the site of MMP-10 cleavage is likely between amino acid 167 (Cp2 site) and 469 (calpain site). Consistent with this, Htt (1-450) is still a substrate for MMP-10 ( Figure 6C) .
To locate the approximate site of cleavage, Htt15Q (1-469) and Htt138Q (1-469) were in vitro translated and incubated with MMP-10. As shown in Figure 6D , MMP-10 addition to Htt15Q (1-469) and Htt138Q (1-469) generates a 48 kDa and 70 kDa fragment, respectively. Htt15Q (1-167), Htt15Q (1-329), Htt15Q (1-378), Htt15Q (1-414), and Htt138Q (1-167) serve as size controls. Analysis of the molecular mass of the Htt15Q cleavage product suggests cleavage occurs around amino acid 414 of Htt. Examination of the amino acid sequence of Htt in this region, and comparison to known MMP substrates, suggests a possible cleavage site at amino acid 402. To test this possibility, we carried out deletion analysis on this site. As shown in Figure 6E , deletion of amino acids 402-403 (DGI) of Htt results in a protein resistant to proteolysis by MMP-10. Htt15Q (1-414), Htt15Q (1-402) and Htt15Q (1-378) serve as size controls. Htt15Q (1-402) matches the molecular mass of the MMP-10-generated Htt cleavage product.
To confirm that the cleavage product is generated in vivo, HD post-mortem cellular lysate were compared to control lysate and analyzed by western blotting. As shown in Figure 6F , a Htt cleavage product around 45-55 kDa is evident in the HD tissue and is consistent with the size of the products in our in vitro assays (accounting for a CAG repeat in the patient of 42). Consistent with this, when we treated HD postmortem cellular lysates with MMP-10 a cleavage product increased at 50 kDa ( Figure 6F) . Further, recent analysis of the HD150 knockin mice suggests Htt fragments of this size are present in striatal and cortical lysates (Landles et al., 2010) . Since Htt is likely to be a substrate via intracellular cleavage by MMP-10, we evaluated localization of endogenous Htt and MMP-10. As shown in Figure 6G , Htt and MMP-10 colocalize in discrete punctate structures (left panel). Further, in cells undergoing cell death Htt and MMP-10 show enhanced colocalization (right panel). Quantification of colocalization is shown in the bar graph of Figure 6G . The colocalization does not result from a direct protein-protein interaction as we did not find MMP-10 and Htt coimmunoprecipitate ( Figure S4 ).
Reduced Activities of MMP and Other Proteases
Identified in the siRNA Screens Improve Neuronal Function in a Drosophila Model of HD The data presented above suggest that reducing the activity of MMPs, and perhaps other proteases, may ameliorate Httinduced neuronal dysfunction in vivo. To test this idea, we used a behavioral readout in a HD Drosophila model expressing the first 336 amino acids of the human protein including 128 glutamines in exon 1. In this model system, neuron-specific expression of expanded Htt leads to quantifiable progressive motor deficits (Kaltenbach et al., 2007) . In contrast to the mammalian genome that contains 25 MMPs with partially overlapping functions, Drosophila only has two MMP family members, Dm1-MMP and Dm2-MMP. Although there are no clear orthologous relationships between the Drosophila and mammalian genes, they are clearly evolutionarily conserved as evidenced by their domain structure, amino acid sequence similarities, and functional interactions (Llano et al., 2000; Page-McCaw, 2003 , 2008 Wei et al., 2003) . Of the two Drosophila genes Dm2-MMP is expressed in the postembryonic brain (Page-McCaw et al., 2003) , while Dm1-MMP expression was not detected in the adult (Llano et al., 2000) . Thus, we asked whether genetically reducing the activity of Dm2-MMP leads to improvement of Htt-induced motor dysfunction. We found that heterozygous loss-of-function alleles of Dm2-MMP show robust and significant effects in improving the motor performance of HD flies. Importantly, this observation was reproduced with two different Dm2-MMP alleles indicating that the effect is caused by reduced function of Dm2-MMP, and not by genetic background effects ( Figures 7A, 7I , and 7J). Figure 7 shows as well that partial loss of function in Drosophila homologs of CAPN5, CAPN7, IMP5, and RNF128 also ameliorate motor deficits in the HD Drosophila model. These data support the idea that MMPs and perhaps other proteases characterized here may be therapeutic targets in HD.
In addition to the behavioral readout, we also tested for photoreceptor degeneration in these flies ( Figure S5 ). Expression of NT-Htt[128Q] in the eye causes severe photoreceptor degeneration, tissue loss and significant shortening in the thickness of the retina when compared to controls ( Figure S5 ). Animals expressing NT-Htt[128Q] and with decreased levels of CalpA, Sol, and Dm2-MMP showed improved retinal integrity and improved thickness when compared to animals expressing NT-Htt[128Q] alone.
DISCUSSION
We have carried out an unbiased RNAi screen to identify proteases that when knocked down reduced the production of toxic N-terminal Htt proteolytic fragments. We screened 514 siRNAs targeting all known and predicted human proteases and found 11 proteases that altered the level of the smallest N-terminal mutant Htt protein detected by the 1C2 anti-polyQ antibody. The proteases identified include members of the calpain family (CAPN5 and CAPN7); the signal peptide protease-like IMP5 and an amino-terminal signal peptide protease (SPC18); members of the secreted serine-protease kallikrein family (KLK10 and KLK11); the transmembrane-E3-ubiquitin ligase, RNF128; the MMP-2 interacting integrin, ITGA2B (Choi et al., 2008b) ; and three members of the matrix metalloproteinase family (MMP-10, MMP-14, MMP-23B).
Our results are consistent with the prior observations demonstrating that calpain family members are involved in the proteolysis of Htt and pathogenesis of HD (Gafni and Ellerby, 2002; Gafni et al., 2004; Kim et al., 2001) . Both CAPN5 and CAPN7 levels are increased in HD mouse models and post-mortem tissue. Several other interesting proteases were identified in our studies. For example, IMP5, a signal peptide peptidase (SPP) is an unusual aspartyl protease that mediates clearance of signal peptides by proteolysis within the endoplasmic reticulum (ER) (Krawitz et al., 2005) . Like presenilins, the proteolytically active subunit of the gamma-secretase complex, SPP contains a critical GXGD motif in its C-terminal catalytic center. Htt is associated with the ER, and perhaps IMP5 plays a role in Htt processing in this organelle (Atwal and Truant, 2008) . Currently the substrates and mechanism for these proteases are unknown. Another identified protease, RNF128, is a ubiquitin E3 ligase, that promotes proteasomal degradation via Lys-48 linkages by capture of transmembrane substrates (Lineberry et al., 2008) . Further studies will be required to determine if Htt is a substrate for RNF128 and how this enzyme alters proteolysis of Htt as observed in our screen. Decreasing the levels of these four proteases (CAPN5, CAPN7, IMP5, and RNF18) suppresses Htt-induced toxicity in mouse striatal cells. Furthermore, knockdown of their Drosophila homologs suppresses neuronal dysfunction in a fly HD model. This underlines their potential as therapeutic targets for HD.
Over 36% of the proteases identified in our screen were matrix metalloproteinase family members, and therefore we focused our analysis on these proteases in HD. In humans, there are 187 metalloproteases, and this represents the largest of the five protease classes (Hornebeck and Lafuma, 1991; Malemud, 2006) . There are 25 human MMPs and four TIMPs. MMPs are traditionally thought to degrade the extracellular matrix, but emerging technology suggests there are many other substrates for MMPs such as chemokines, cell receptors, cyotokines, growth factors and fas ligands. We found that the knockdown of the MMP-2 interacting integrin ITGA2B (Choi et al., 2008b) and three members of the matrix metalloproteinase family (MMP-10, MMP-14, MMP-23) suppressed toxicity in an immortalized striatal cell line harboring a knock-in of mutant Htt. We show that MMP activity is increased in cell culture and animal models of HD. Furthermore, MMP-10 is proteolytically processed and activated in these models. Relevant to our studies, MMP-10 is known to be upregulated in stroke and is present in neurons (Cuadrado et al., 2009) .
The mechanism by which MMPs suppress HD-mediated toxicity could be through the known function of MMPs in targeting the extracellular matrix or cytokines (see Figure 8 for potential mechanisms). However, our screen was designed to identify proteases that when knocked down would reduce the in the nervous system but with decreased levels of the proteases: CalpA (CAPN5 homolog, B-C); Sol (CAPN7 homolog, E); Spp (IMP5 homolog, F); CG17370 (IMP5 homolog, G-H); Dm2-MMP (MMP homolog, I-J) or Gol (RNF18 homolog, K) show improved motor performance (red solid line in Band C and E-H). In contrast, flies expressing NT-Htt[128Q] with increased levels of the protease Sol (CAPN7 homolog) display a worse motor performance (red solid line in D). Data was analyzed using ANOVA followed by Tukey's hsd. Error bars represent SEM. *p < 0.01, **p < 0.001, ***p < 0.0001. Flies were raised at 26.5 C.
See also Figure S5 .
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Matrix Metalloproteinases Modify Huntingtin proteolysis of mutant Htt. In order to determine the mechanism for MMPs in HD, we evaluated whether Htt is a substrate for particular MMP family members. We found that MMP-10 cleaves Htt directly whereas MMP-14 and MMP-2 do not. Inhibition of MMP-10 by siRNA-mediated knockdown reduces the generation of the smallest detectable N-terminal polyQ-containing fragment of Htt in cell culture. We mapped the cleavage site of Htt generated by MMP-10 to amino acid 402. It is noteworthy that the MMP-10 cleavage site in Htt is highly conserved, with (S/T)XXGG(I/L) being present from human to Fugu. These results suggest that knockdown of MMP-10 reduces HD toxicity through directly effecting the proteolysis of Htt. For the other MMP family members, known mechanisms of cleavage of extracellular matrix or cytokines is likely to play a significant role in reducing HD-mediated toxicity. Recent evidence suggests that some matrix metalloproteinase family members such as MMP-3 function inside the cell during neuronal cell death (Choi et al., 2008a) . While MMPs are generally thought to be secreted as proenzymes and processed to their active forms outside the cell, we found that MMP-10 was activated inside the cell. This has been reported for other MMPs (Luo et al., 2002; Weiss, 1995, 1996) . Furthermore, we found that MMP-10 and Htt colocalize, suggesting the possibility that cleavage occurs intracellularly. Htt is known to associate with membranes and has a site of palmitoylation that would allow proteolysis to occur at the membrane surface (Kegel et al., 2009a (Kegel et al., , 2009b Yanai et al., 2006) . Activation of MMPs is known to occur in diseases including stroke, cancer and HIV (Malemud, 2006) . In our study, we found In HD striatal cells, MMP-10 and MMP-14 are activated. Upon activation, MMPs may cause neurotoxicity at different cellular locations/substrates in our model. Htt may be processed directly or indirectly by MMPs (through activation of other proteases). In striatal neurons, MMP-10 may process mutant Htt into a toxic fragment intracellularly and possibly processing other cellular substates. Proteolysis of these substrates would activate cell death. On the outside of the cell (MMP is membrane bound or secreted), proteolysis of extracellular substrates could result in processing of substrates involved in inflammation. This could also occur in glia as depicted in our model.
MMPs to be activated in cellular and animal HD models. Knockdown of particular MMP family members reduced mutant Htt-mediated cell death in an immortalized striatal cell line and significantly improved motor deficits caused by neuronal expression of polyQ-expanded Htt in Drosophila. These data suggest that selective inhibition of the implicated MMP family members should be considered for developing novel therapeutics for HD. For example, MMP-9 knockout mice show improved outcomes after cerebral ischemia (Asahi et al., 2000) . This may be directly relevant to HD as a recent analysis of postmortem HD revealed MMP-9 is upregulated in HD brain and absent in age-matched controls (Silvestroni et al., 2009 ). AG3340 (prinomastat), a small molecule hydroxamate-based inhibitor of MMPs, was examined in a model of chronic cerebral hypoperfusion and is neuroprotective in adult rats and mice when administered just before insult (Cai et al., 2006) . Reduced activation of astrocytes and microglia was also associated with retained blood-brain barrier integrity in these studies. In addition, in a mouse model of middle cerebral artery occlusion, the gelatinase-selective compound SB-3CT reduced infarct volume when administered starting at either 2 or 6 hr after insult (Gu et al., 2005) .
Taken together, our results suggest that general inhibition of MMPs may be of therapeutic benefit in Huntington's disease and that specific inhibitors of MMP-10 may be particularly relevant to disease treatment.
EXPERIMENTAL PROCEDURES
Plasmid Constructs
The full-length expanded polyQ Htt expression construct, Htt138Q, and pcDNA 3.1 (Invitrogen), were used for the western blotting screen (Martindale et al., 1998) . For evaluating MMP proteolysis of Htt with recombinant enzymes, human Htt constructs expressing the first 469, 414, 402, 378, 329, and 167 amino acids were made by site-directed mutagenesis of the Htt 15Q and 138Q (1-1212) constructs (Wellington et al., 2000) . Amino acids 167 to 170 were deleted in Htt 15Q (1-1212) and 402 to 403 were deleted in Htt 15Q (1-450) were used for western analysis (Kaltenbach et al., 2007) .
Htt Proteolysis Western Blot Primary Screen
We screened Dharmacon's siGENOME SMARTPOOL Protease Set consisting of 514 protease siRNA pools of four duplexes for their ability to reduce the abundance of a mutant Htt N-terminal fragment. Human embryonic kidney 293T (HEK293T) cells were cultured in Dulbecco's modified eagle medium (DMEM; Mediatech) containing penicillin/streptomycin (100 units/ml/ 100 mg/ml) and 10% heat-inactivated fetal bovine serum (FBS) (GIBCO). Cells were seeded in DMEM with 10% serum without penicillin/streptomycin at 5 3 10 4 cells/well in collagen-coated 96-well plates (BD, Biocoat) and incubated at 37 C for 24 hr. Lipofectamine 2000 (Invitrogen) was used for transient transfections according to manufacturer's instructions. Cells were transfected with 80 ng of DsRed DNA, 0.32 mg pcI-Htt138Q DNA, 136 nM siRNA and 1 mg Lipofectamine 2000 in 25 ml DMEM lacking serum or penicillin/streptomycin. After a 48 hr incubation at 37 C, media was replaced with DMEM containing 10%
FBS and 1 mM epoxomicin and incubated for an additional 24 hr. Cells were lysed directly in wells with 25 ml M-PER (Thermo Scientific) containing protease inhibitors (1 tablet/10 ml, Complete Mini, EDTA-free, Roche) and RQ1 DNase (Promega) and 1 mM MgCl 2 . Plates were shaken at 700 rpm for 10 min. To 10 ml of lysate, 6 ml of 43 LDS loading buffer (Invitrogen) and 1 ml of 1M DTT was added and heated to 99 C for 5 min. Lysate proteins were resolved on 4%-12% bis-tris gels, transferred to nitrocellulose membrane, and probed with monoclonal antibody MAB1574 (1C2, 1:2000, Chemicon). Multiple film exposures were collected for each blot, and nonsaturated films were scanned and analyzed by densitometry using ImageQuant TL. Hits were identified as those siRNAs which reduced the amount of the 55 kDa band (relative to the FL Htt) by 30% or more in duplicate. The 41 siRNAs that met these criteria were then retested in triplicate.
Secondary Screen for Caspase 3/7 Activity Suppression in Striatal Hdh 7Q/7Q and Hdh 111Q/111Q Cells
Striatal cell lines cells were nucleofected with siRNA as described below, plated at 5 3 10 4 cells/well on collagen-coated 96-well plates, and incubated for 48 hr in DMEM containing 10% FBS and 100U/ml/100 mg/ml penicillin/ streptomycin, followed by serum-deprivation for 24 hr before assaying. Cells were lysed in 50 ml of a 50/50 mixture of DMEM/Apo Lysis Buffer (Cell Technology Inc). Aliquots (10 ml) were taken for protein quantification by the BCA method (Pierce) before the addition of DMEM/Apo Lysis Buffer with 20 mM DTT and 2% APO 3/7 HTS Substrate (Cell Technology, Inc. in a humidified atmosphere of 95% air and 5% CO 2 , in DMEM containing 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin. RNAi treatment of cells was as follows: 1 3 10 6 cells per siRNA treatment were collected and nucleofected using Kit L (Amaxa) with 3 mg of siRNA, and then 6 3 10 5 cells/well were plated on 6-well plates. After 48 hr incubation, cells were serum starved for 24 hr followed by harvesting for analysis by western blotting. For western blotting without siRNAs the cells were treated with and without serum. Cells were resuspended in M-PER with protease inhibitors (1 tablet/10 ml, Complete Mini, EDTA-free, Roche). Whole-cell lysates were sonicated 5 3 5 s pulses at 40 mA. Samples were centrifuged at 22K rpm and supernatant was collected for western blotting. 43 LDS sample buffer (Invitrogen) and 1 ml of 1M DTT were added to 20-40 mg total protein and boiled for 10 min. Samples were resolved by SDS-PAGE using 4%-12% NuPage Bis-Tris gels under reducing conditions in MES running buffer. Gels were run at a constant 200V for 1 hr, transferred to 0.45 mm nitrocellulose membranes in 13 NuPage transfer buffer for 8 hr at 20V. Membranes were incubated in TBS with 0.1% Tween 20 (TBS-T), 5% non-fat milk for 1 hr. Primary antibodies anti-MMP-10 (1:5000, Abcam ab28205), MMP-14 (1:2000, Abcam ab51074), MMP-23 (1: 500, Abcam ab5314); anti-polyQ (1:2000, Chemicon, MAB1574); and anti-Htt (1:500, MAB2166; 1:1000, MAB5490; 1:1000, MAB5492; 1:100 MAB5374, all from Chemicon); anti-tubulin (1:1000, Sigma); and anti-b-actin (1:1000, Cell Signaling) were diluted into TBS with 0.1% Tween 20 (TBS-T), 5% non-fat milk for 1 hr. Blots were developed using Pierce ECL (Thermo Scientific). Band intensity was quantified using ImageQuant TL v2005.
RT-PCR of Striatal Cell Knockdown and Mouse Tissue mRNA
Total RNA was isolated from electroporated striatal cells (1 well of a 6-well plate) or striatal mouse tissue with the RNeasy Mini Kit (QIAGEN) according to the manufacturer's instructions. One microgram of RNA was converted to cDNA by using the Message Sensor RT kit (Applied Biosystems). Real-time quantitative PCR (qPCR) was performed with either Universal Probe Library dye (UPL from Roche) or SYBR Green (Applied Biosystems) on the LightCycler 480 system (Roche). For quantification the threshold cycle Cp of each amplification was determined by the second derivative analysis provided by the LightCycler 480 software and the 2 -DDCp method was used to determine the relative expression level of each gene normalized against the house-keeping gene b-actin. The specificity of each pair of primers was tested by comparing to a negative control sample of water on both quantification analysis and high resolution melting curve analysis. The primers used are as follows: MMP10 F,
MMP Cell Activity Assays
Striatal Hdh 7Q/7Q and Hdh 111Q/111Q cell pellets or mouse striatal tissue were lysed in M-PER or T-PER (Thermo Scientific), respectively. MMP enzyme activity was measured using the MMP assay kit (Biomol) per the manufacturer's protocol with the fluorogenic substrate Mca-Pro-Leu-Dpa-Ala-Arg-NH 2 (Mca = (7-methoxycoumarin-4-yl)-acetyl; Dpa = N-3(2,3-dinitrophenyl)-L-a-b-diaminopropionyl). Fluorescence was normalized to total protein in the lysate.
Gelatinase Gel Zymography
Gelatinase activity from cortex and striatum of R6/2 and control mouse tissue lysates (T-PER) was measured following affinity purification. Briefly, 500 mg of total protein was added to 500 ml lysis buffer (50 mM Tris-HCl [pH 7.6], 150 mM NaCl, 5 mM CaCl 2 , 0.05% Brij-35, 1% Triton X-100, and 0.02% NaN3) and affinity purified over gelatin Sepharose (GE Healthcare). MMP protein was eluted with 10% DMSO in PBS. One hundred fifty micrograms of purified lysate was added to three microliters of 63 SDS buffer and resolved on a 10% zymogram gel (Invitrogen) containing 0.1% gelatin. Following electrophoresis, gels were incubated in 2.7% Triton X-100 at room temperature for 30 min then placed in developing buffer, 50 mM Tris-HCl (pH 7.6), 200 mM NaCl, 5 mM CaCl 2 , and 0.05% Brij-35, for 72 hr at 37 C. After developing, gels were stained in SimplyBlue (Invitrogen) for 1 hr at room temperature and destained in ddH 2 O overnight. Gelatinase activity was detected as a clearing of the blue-stained gelatin. Mouse tissue was collected in accordance protocols approved by IACUC.
In Situ Zymography, Immunohistochemistry of R6/2, and Control Brain Sections R6/2 and control mice were perfused with ice cold PBS (pH 7.4), and brain tissue was collected and immediately frozen on dry ice. Frozen 20 mm sagittal sections were mounted on slides and quickly exposed to zymography solution of pH 7.4 containing 50 mM Tris-HCL, 150 mM NaCl, 5 mM CaCl 2 , 0.3 mM NaN 3, and 40 mg DQ gelatin (Molecular Probes, Eugene, OR) overnight at 37 C. Control slides included 1 mM 1-10-phenanthroline MMP inhibitor. Reaction products were visualized on a confocal microscope (LSM510, Zeiss). In situ zymography sections were fixed in 4% PFA in PBS, permeabilized in 1% Tween in 13 TBS, blocked in 10% normal donkey serum with chicken antimouse IgG at 1:500. Primary antibodies were diluted in 1% BSA in 13 TBS and incubated 24 hr at 4 C. All washes were done 3 3 10 min in 1X TBS. Secondary antibody was diluted in 1% BSA in 13 TBS and applied to slices for 1 hr. MAB5374 Htt(82-150) antibody (1:50, Chemicon) was labeled with Alexa 647 donkey anti-mouse (Molecular Probes); and GFAP (1:500, Sigma) was labeled with Alexa 555 donkey anti-rabbit (Molecular Probes). Following incubation in secondary antibody, slices were washed and mounted in Prolong Gold (Invitrogen) with DAPI.
In Vitro Protein Synthesis and Cleavage Htt15Q (1-1212), Htt15Q (1-469), Htt138Q (1-469), Htt 15Q (1-414), Htt 15Q (1-402), Htt 15Q (1-378), Htt 15Q (1-329), Htt15Q (1-167), Htt138Q (1-167), Htt15Q (1-1212) D167-170 and Htt 15Q(1-469) D402-403 constructs were translated with TNTCoupled Reticulocyte Lysate Systems kit (Promega). Three microliters of translation product was diluted in M-PER and 10 U of the catalytic domain of MMP-2, MMP-10, or MMP-14 (Biomol) were added and incubated for 2 hr at 37 C. Following addition of SDS and DTT, samples were heated to 90 C for 10 min and run on 12% Bis-Tris gels. Gels were fixed and dried before exposing to film.
Immunocytochemistry of Striatal Hdh 111Q/111Q Cells
Immunocytochemistry was performed on Hdh 111Q/111Q cells cultured with serum or 24 hr serum depravation. Cells were fixed in 4% PFA in PBS for 20 min and washed 5 min in 13 PBS and 23 5 min in 13 TBS. Blocking, primary antibodies, secondary antibodies, and washes were applied according to in situ procedure described above. MAB5490 antibody Htt (115-129) (1:500, Chemicon) was labeled with Alexa 555 donkey anti-mouse (Molecular Probes) and MMP10 antibody (1:2000, Abcam) was labeled with Alexa 488 donkey anti-rabbit. Cells were washed 3 3 5 min in 13 TBS and mounted in Prolong Gold (Invitrogen) with DAPI. 
